Literature DB >> 10186477

The role of cost-effectiveness analysis in managed-care decisions.

H Grabowski1.   

Abstract

This article considers the role of cost-effectiveness studies in the formulary and disease-state management decisions of managed-care entities. In a recently published symposium volume [Soc Sci Med 1997; 45 (4): 505-647], US managed-care entities were found to be among the leaders in applying cost-effectiveness studies to healthcare decisions. At the same time, a number of barriers were identified that hinder their wider usage in the managed-care sector. These factors are analysed in this paper along with the prospects for future changes. The potential roles for government policy in this area are also discussed in the final section of the article.

Mesh:

Year:  1998        PMID: 10186477     DOI: 10.2165/00019053-199814001-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  13 in total

Review 1.  Pharmacy benefit management companies (PBMs). Why should we be interested?

Authors:  S R Shulman
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

2.  The Oregon experiment: the role of cost-benefit analysis in the allocation of Medicaid funds.

Authors:  J F Blumstein
Journal:  Soc Sci Med       Date:  1997-08       Impact factor: 4.634

3.  The FDA and regulation of cost-effectiveness claims.

Authors:  P J Neumann; D E Zinner; A D Paltiel
Journal:  Health Aff (Millwood)       Date:  1996       Impact factor: 6.301

4.  The impact of cost-effectiveness on public and private policies in health care: an international perspective. Introduction and overview.

Authors:  F A Sloan; H G Grabowski
Journal:  Soc Sci Med       Date:  1997-08       Impact factor: 4.634

5.  Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions.

Authors:  H Grabowski; C D Mullins
Journal:  Soc Sci Med       Date:  1997-08       Impact factor: 4.634

6.  Making economic evaluations respectable.

Authors:  U E Reinhardt
Journal:  Soc Sci Med       Date:  1997-08       Impact factor: 4.634

7.  Managed care pharmacy, socioeconomic assessments and drug adoption decisions.

Authors:  A Lyles; B R Luce; A M Rentz
Journal:  Soc Sci Med       Date:  1997-08       Impact factor: 4.634

Review 8.  Misoprostol: pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs.

Authors:  L B Barradell; R Whittington; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

9.  Cost effectiveness of vaccination against pneumococcal pneumonia.

Authors:  J S Willems; C R Sanders; M A Riddiough; J C Bell
Journal:  N Engl J Med       Date:  1980-09-04       Impact factor: 91.245

10.  Cholesterol-reduction intervention study (CRIS): a randomized trial to assess effectiveness and costs in clinical practice.

Authors:  G Oster; G M Borok; J Menzin; J F Heyse; R S Epstein; V Quinn; V Benson; R J Dudl; A M Epstein
Journal:  Arch Intern Med       Date:  1996-04-08
View more
  1 in total

1.  Pharmacoeconomics and health policy. Current applications and prospects for the future.

Authors:  P E Greenberg; A Arcelus; H G Birnbaum; P Y Cremieux; J LeLorier; P Ouellette; M B Slavin
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.